[CAS NO. 41270-96-6] 4-IPP
PRODUCTS SPECIFICATIONS [41270-96-6]
DESCRIPTION [41270-96-6]
Overview
| MDL | MFCD00234609 |
|---|---|
| Molecular Weight | 282.08 |
| Molecular Formula | C10H7IN2 |
| SMILES | IC1=CC(C2=CC=CC=C2)=NC=N1 |
1 Publications Citing Use of MCE
Summary
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF) [1] .
IC50 & Target
MIF [1]
In Vitro
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity
[1]
.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes
[1]
.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation
[1]
.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner
[1]
.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
| Cell Line: | BMMs |
| Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM |
| Incubation Time: | 24 hours, 72 hours |
| Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis [1]
| Cell Line: | BMMs |
| Concentration: | 5 μM,10 μM, 20 μM |
| Incubation Time: | 1 day, 3 days, 5 days |
| Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
In Vivo
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 8-weeks-old C57BL/6J male mice [1] |
| Dosage: | 1 mg/kg, 5 mg/kg |
| Administration: | Intraperitoneal injection; every 2 days; for 8 weeks |
| Result: | Alleviated OVX-induced osteoporosis. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 886.27 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5451 mL | 17.7255 mL | 35.4509 mL |
| 5 mM | 0.7090 mL | 3.5451 mL | 7.0902 mL |
| 10 mM | 0.3545 mL | 1.7725 mL | 3.5451 mL |